Business Trends– category –
-
Korsana Biosciences Secures $380 Million in PIPE Financing to Advance Alzheimer’s Disease Pipeline
Panabee (Korsana Biosciences) United States Overview On September 10, 2026, Korsana Biosciences successfully completed a $380 million PIPE (Private Investment in Public Equity) financing to accelerate its Alzheimer's disease (AD) therape... -
Samsung Biologics Secures $262M Manufacturing Contract with European Pharma Amid Peptide Expansion and CDMO Capacity Growth
BioProcess International South Korea Overview On September 10, 2026, Samsung Biologics announced a $262 million manufacturing agreement with an undisclosed European pharmaceutical company. This substantial contract will further accelerat... -
Evonik Breaks Ground on Biotechnology Expansion in Slovakia, Strengthening European Pharmaceutical Manufacturing Hub
Evonik Germany Overview On September 14, 2026, Evonik initiated construction for a significant biotechnology manufacturing expansion at its Fermín site in Slovakia. This investment aims to bolster the company's production capacity for ac... -
Rani Therapeutics Achieves 84% Bioavailability for Oral Ustekinumab Biosimilar; Oral GLP-1s Drive Commercial Success in Biopharma Delivery
Drug Delivery Leader USA Overview The successful FDA approval and commercial launch of oral semaglutide (Wegovy) and orforglipron highlight the critical role of oral delivery in chronic disease management, significantly improving patient... -
OS Therapies Strengthens FDA & MHRA Alignment, Joins Project Orbis for OST-HER2 Metastatic Osteosarcoma Program
OS Therapies USA Overview OS Therapies announced strengthened alignment with the FDA and MHRA and approval to join Project Orbis for its lead candidate, OST-HER2 (a next-generation tunable ADC) program for metastatic osteosarcoma. Projec... -
Nutshell Therapeutics’ NRF2 Molecular Glue Degrader NTS231 Clears FDA IND, Becomes China’s First and World’s Second to Enter Clinical Development
Insight, China's Pharmaceutical Industry China Overview Nutshell Therapeutics' NRF2 molecular glue degrader, NTS231, has cleared FDA IND, becoming the first from China and second globally to enter clinical development as a novel therapeu... -
Akeso’s EGFR/TROP2 Bispecific ADC AK158D1 Cleared for Phase I Clinical Trial in Advanced Solid Tumors by China’s NMPA
PR Newswire China Overview Akeso Inc., a Chinese biopharmaceutical company, announced that its EGFR and TROP2 bispecific antibody-drug conjugate (ADC) candidate, AK158D1, has received clearance from China's National Medical Products Admi...
1